Mifepristone has been approved for abortion in the United States for over 25 years and has been used by more than 7.5 million women. It is also effective in treating conditions such as uterine fibroids and endometriosis. Special correspondent Sarah Varney and producer Rachel Wellford report on these treatments amid ongoing lobbying by anti-abortion groups to impose further restrictions on these drugs. This report is part of the series "Beyond Abortion."
Mifepristone, along with a similar drug, has been shown to alleviate common and painful women's health issues. Deja Cradle, who experienced severe menstrual pain from a young age, was diagnosed with uterine fibroids after years of suffering. Fibroids, which are non-cancerous growths in the uterus, affect a significant number of women, with studies indicating that 70% of white women and over 80% of Black women will develop them by age 50. Symptoms can include extreme pain and infertility, and treatment often requires invasive procedures.
Dr. Abby Liberty from Oregon Health and Science University notes that there are effective non-invasive treatments available, including mifepristone and an emergency contraceptive. These medications can reduce fibroid size by up to 50%, but they are not widely accessible in the U.S. due to political pressures and restrictions.
Anti-abortion groups have campaigned against mifepristone, questioning its safety and effectiveness for non-abortion related conditions. Recent actions by the Trump administration and lawsuits in states like Louisiana, Texas, and Florida aim to further limit access to these drugs.
Dr. Liberty and other researchers argue that these restrictions hinder advancements in women's health. Danielle Shoback, who suffered from debilitating menstrual symptoms, sought alternative treatments after finding limited options through traditional medical channels. She discovered that mifepristone could alleviate her symptoms but faced skepticism from medical professionals.
Dr. Rebecca Gomperts, a physician and researcher, emphasizes the safety and efficacy of these medications, advocating for broader access. She highlights the disparity in treatment options available to women in the U.S. compared to those in Europe, where similar restrictions do not exist.
The ongoing debate over mifepristone and related medications raises concerns about the potential impact on women's health outcomes. As women like Deja Cradle and Danielle Shoback advocate for their health rights, the future of access to these treatments remains uncertain. The next report in this series will explore further potential uses of these drugs, including cancer prevention, and the challenges faced in the U.S.